Multiple endocrine neoplasia type 1 screening: Difference between revisions
No edit summary |
|||
Line 3: | Line 3: | ||
{{CMG}}; {{AE}} {{Ammu}} | {{CMG}}; {{AE}} {{Ammu}} | ||
==Overview== | ==Overview== | ||
According to the National Caner Institute, screening for multiple endocrine neoplasia type 1 by serum prolactin and/or insulin-like growth factor 1 is recommended every year among patients with [[pituitary tumor]]s, fasting total serum calcium and/or ionized calcium and parathyroid hormone is recommended every year among patients with [[parathyroid tumor]]s, fasting serum gastrin every year among patients with duodenopancreatic [[gastrinoma]], chromogranin A, pancreatic polypeptide, glucagon, and vasointestinal polypeptide every 5 year and abdominal CT, MRI, or endoscopic US every year among patients with [[pancreatic neuroendocrine tumor]]s and [[primary hyperparathyroidism]], and brain MRI every 3-5 years among patients with [[pituitary tumor]]s. | |||
==Screening== | ==Screening== | ||
Screening and surveillance for MEN1 may employ a combination of biochemical tests and imaging. Available recommendations are summarized in the following table.<ref name=NCI>{{cite web | title = National Caner Institute Multiple endocrine neoplasia type 1 Surveillance| url =http://www.cancer.gov/types/thyroid/hp/medullary-thyroid-genetics-pdq#link/_775_toc }}</ref> | Screening and surveillance for MEN1 may employ a combination of biochemical tests and imaging. Available recommendations are summarized in the following table.<ref name=NCI>{{cite web | title = National Caner Institute Multiple endocrine neoplasia type 1 Surveillance| url =http://www.cancer.gov/types/thyroid/hp/medullary-thyroid-genetics-pdq#link/_775_toc }}</ref> |
Revision as of 17:19, 8 September 2015
Multiple endocrine neoplasia type 1 Microchapters |
Differentiating Multiple endocrine neoplasia type 1 from other Diseases |
---|
Diagnosis |
Treatment |
Case Studies |
Multiple endocrine neoplasia type 1 screening On the Web |
American Roentgen Ray Society Images of Multiple endocrine neoplasia type 1 screening |
Directions to Hospitals Treating Multiple endocrine neoplasia type 1 |
Risk calculators and risk factors for Multiple endocrine neoplasia type 1 screening |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Ammu Susheela, M.D. [2]
Overview
According to the National Caner Institute, screening for multiple endocrine neoplasia type 1 by serum prolactin and/or insulin-like growth factor 1 is recommended every year among patients with pituitary tumors, fasting total serum calcium and/or ionized calcium and parathyroid hormone is recommended every year among patients with parathyroid tumors, fasting serum gastrin every year among patients with duodenopancreatic gastrinoma, chromogranin A, pancreatic polypeptide, glucagon, and vasointestinal polypeptide every 5 year and abdominal CT, MRI, or endoscopic US every year among patients with pancreatic neuroendocrine tumors and primary hyperparathyroidism, and brain MRI every 3-5 years among patients with pituitary tumors.
Screening
Screening and surveillance for MEN1 may employ a combination of biochemical tests and imaging. Available recommendations are summarized in the following table.[1]
Biochemical Test or Procedure | Condition Screened For | Age Screening Initiated (y) | Frequency |
---|---|---|---|
Serum prolactin and/or insulin-like growth factor 1 | Pituitary tumors | 5 | Every 1 year |
Fasting total serum calcium and/or ionized calcium and parathyroid hormone | Parathyroid tumors and primary hyperparathyroidism | 8 | Every 1 year |
Fasting serum gastrin | Duodenopancreatic gastrinoma | 20 | Every 1 year |
Chromogranin A, pancreatic polypeptide, glucagon, and vasointestinal polypeptide | Pancreatic neuroendocrine tumors | <10years | Every 1 year |
Fasting glucose and insulin | Insulinoma | 5 | Every 1 year |
Brain MRI | Pituitary tumors | 5 | Every 3–5 year based on biochemical results |
Abdominal CT or MRI | Pancreatic neuroendocrine tumors | 20 | Every 3–5 year based on biochemical results |
Abdominal CT, MRI, or endoscopic US | Pancreatic neuroendocrine tumors | <10 | Every 1 year |